At present, there is a favourable situation in the market for the development of biosimilar therapeutic proteins and the development of technologies for their production. In the USA and Europe, a part of the patent protection period for pharmaceutical innovators has expired, part of which will expire by 2022. Therefore, the development of biosimilar therapeutic protein production technologies is commercially viable. The main problem in the biopharmaceutical market is the high price of biotechnological medicines, which limits their availability. Currently, the biopharmaceutical market has created a niche position — when most companies focus on mammalian cell-produced products (in particular monoclonal antibodies), the market for microbial products (insulins, interferons, human growth hormone, granulocyte colony stimulating factor, some rarer monoclonal antibodies, FAB fragments, etc.) has been relatively good. During the project Biotechpharma plans to create a modern R & D infrastructure for microbial products in which it could research, develop and develop microbial production technologies. During the project, it is planned to develop a prototype of biosimilar long-acting insulin glargine production technology together with the partner — Innovative Medicine Centre.